GordonMD® Global Investments Portfolio Company, Radionetics Oncology, Announced Strategic Agreement with Lilly
Radionetics Oncology Enters Into Strategic Agreement With Lilly
Eli Lilly is continuing to pursue its newfound passion for radiopharmaceuticals, this time handing Radionetics Oncology $140 million in upfront cash to partner on its pipeline of G protein coupled receptor (GPCR) targeted drugs.